49 results on '"Kolarova T"'
Search Results
2. Brain Plasticity in fMRI and DTI
- Author
-
Karahasanović, N., primary, Gruber, T., additional, Dörl, G., additional, Radjenovic, S., additional, Kolarova, T., additional, Matt, E., additional, and Beisteiner, R., additional
- Published
- 2021
- Full Text
- View/download PDF
3. ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors
- Author
-
Borbath, I., Pape, U. -F., Deprez, P. H., Bartsch, D. K., Caplin, M., Falconi, M., Garcia-Carbonero, R., Grozinsky-Glasberg, S., Jensen, R. T., Arnold, R., Ruszniewski, P., Toumpanakis, C., Valle, J. W., O'Toole, D., Belli, S. H., Castano, J. P., Chen, J., Costa, F. P., Couvelard, A., de Herder, W. W., Deroose, C. M., Dromain, C., Faggiano, A., Falkerby, J., Fazio, N., Frilling, A., Grande, E., Hand, P., Hicks, R. J., Horsch, D., Howe, J. R., Kloppel, G., Kolarova, T., Kos-Kudla, B., Koumarianou, A., Krejs, G. J., Krenning, E. P., Krishna, B. A., Leyden, S., Masui, T., Niederle, B., Nieveen van Dijkum, E. J., Oberg, K., Pavel, M., Perren, A., Prasad, V., Ramage, J. K., Reed, N. S., Rindi, G., Gemelli, A., Rinke, A., Rothmund, M., Singh, S., Sundin, A., Velthuysen, M. F. V., Verslype, C., Vullierme, M. P., Welin, S., Wiedenmann, B., Zhao, H., Graduate School, Surgery, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, and UCL - (SLuc) Unité d'oncologie médicale
- Subjects
Cellular and Molecular Neuroscience ,Neuroendocrine Tumors ,Endocrinology ,neuroendocrine neoplasms ,Endocrine and Autonomic Systems ,Endocrinology, Diabetes and Metabolism ,Humans ,Endoscopy ,endoscopy ,standardised reporting - Abstract
Despite efforts from various endoscopy societies, reporting in the field of endoscopy remains extremely heterogeneous. Harmonisation of clinical practice in endoscopy has been highlighted by application of many clinical practice guidelines and standards pertaining to the endoscopic procedures and reporting are underlined. The aim of the proposed "standardised reporting" is to (1) facilitate recognition of gastrointestinal neuroendocrine neoplasms (NEN) on initial endoscopy, (2) to enable interdisciplinary decision making for treatment by a multidisciplinary team, (3) to provide a basis for a standardised endoscopic follow-up which allows detection of recurrence or progression reliably, (4) to make endoscopic reports on NEN comparable between different units, and (5) to allow research collaboration between NEN centres in terms of consistency of their endoscopic data. The ultimate goal is to improve disease management, patient outcome and reduce the diagnostic burden on the side of the patient by ensuring the highest possible diagnostic accuracy and validity of endoscopic exams and possibly interventions.
- Published
- 2022
4. European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states
- Author
-
Blay, J-Y, Casali, P, Bouvier, C, Dehais, C, Galloway, I, Gietema, J, Halámková, J, Hindi, N, Idbaih, A, Kinloch, E, Klümpen, H-J, Kolarova, T, Kopeckova, K, Lovey, J, Magalhaes, M, Oselin, K, Piperno-Neumann, S, Ravnsbaek, A, Rogasik, M, Safwat, A, Scheipl, S, Seckl, M, Taylor, J, Temnyk, M, Trama, A, Urbonas, M, Wartenberg, M, Weinman, A, EURACAN Network, Oncology, CCA - Cancer Treatment and Quality of Life, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon], University of Milan, Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan], Royal Free Hospital [London, UK], Service de neurologie 2 [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), University Medical Center Groningen [Groningen] (UMCG), Masaryk Memorial Cancer Institute (RECAMO), Hospital Universitario Virgen del Rocío [Sevilla], University of Amsterdam [Amsterdam] (UvA), University Hospital Motol [Prague], National Institute of Oncology [Budapest, Hungary], Centro Hospitalar do Porto, North Estonia Medical Center, Institut Curie [Paris], Aarhus University Hospital, Karl-Franzens-Universität [Graz, Autriche], Charing Cross Hospital & Imperial College, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Kaunas University of Technology (KTU), EURORDIS-Rare Diseases Europe (Bureau de Paris), EURORDIS - Plateforme Maladies Rares [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and University of Graz
- Subjects
Cancer Research ,medicine.medical_specialty ,Statement (logic) ,MEDLINE ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,News ,GUIDELINES ,DIAGNOSIS ,03 medical and health sciences ,0302 clinical medicine ,EURACAN Network ,Health care ,medicine ,030212 general & internal medicine ,ComputingMilieux_MISCELLANEOUS ,business.industry ,Member states ,3. Good health ,Oncology ,030220 oncology & carcinogenesis ,Family medicine ,SURVIVAL ,Position paper ,SARCOMA PATIENTS ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,BURDEN - Abstract
International audience
- Published
- 2021
5. 1113P Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America
- Author
-
Kolarova, T., primary, McDonnell, M., additional, Bouvier, C.V., additional, Pavel, M.E., additional, Singh, H., additional, Howe, J., additional, Singh, S., additional, O'Toole, D., additional, Chen, J., additional, Leyden, S., additional, Gellerman, E., additional, Dureja, S., additional, Rodien-Louw, C., additional, and Van Genechten, D., additional
- Published
- 2021
- Full Text
- View/download PDF
6. P-92 The neuroendocrine tumor diagnostic process and the role of gastrointestinal specialists
- Author
-
Leyden, S., primary, McDonnell, M., additional, Bouvier, C., additional, Pavel, M., additional, Singh, H., additional, Howe, J., additional, O’Toole, D., additional, Van Genechten, D., additional, Dureja, S., additional, Rodien-Louw, C., additional, Kolarova, T., additional, and Gellerman, E., additional
- Published
- 2021
- Full Text
- View/download PDF
7. 1168P Survey of challenges in access to diagnostics and treatment for neuroendocrine tumour (NET) patients (SCAN): Healthcare quality evaluation
- Author
-
Bouvier, C.V., primary, Van Genechten, D., additional, Kolarova, T., additional, McDonnell, M., additional, O'Toole, D., additional, Singh, H., additional, Chen, J., additional, Howe, J., additional, Singh, S., additional, Rodien-Louw, C., additional, Leyden, S., additional, and Dureja, S., additional
- Published
- 2020
- Full Text
- View/download PDF
8. P-136 Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor patients (SCAN): Early diagnosis and treatment availability
- Author
-
Kolarova, T., primary, McDonnell, M., additional, Van Genechten, D., additional, Bouvier, C., additional, Rodien-Louw, C., additional, Dureja, S., additional, and Leyden, S., additional
- Published
- 2020
- Full Text
- View/download PDF
9. Unmet needs in the management of neuroendocrine tumours (NETs): A global survey of patients, patient advocates and healthcare professionals
- Author
-
Bouvier, C.V., primary, Caplin, M., additional, Conroy, S., additional, Davies, P., additional, Dureja, S., additional, Falconi, M., additional, Ferolla, P., additional, Fisher, G.A., additional, Goldstein, G., additional, Hicks, R.J., additional, Hollander, R., additional, Kolarova, T., additional, Lawrence, B., additional, Leyden, S., additional, Majima, Y., additional, Metz, D., additional, O’Toole, D., additional, Ruszniewski, P., additional, and Wiedenmann, B., additional
- Published
- 2018
- Full Text
- View/download PDF
10. 1328P - Unmet needs in the management of neuroendocrine tumours (NETs): A global survey of patients, patient advocates and healthcare professionals
- Author
-
Bouvier, C.V., Caplin, M., Conroy, S., Davies, P., Dureja, S., Falconi, M., Ferolla, P., Fisher, G.A., Goldstein, G., Hicks, R.J., Hollander, R., Kolarova, T., Lawrence, B., Leyden, S., Majima, Y., Metz, D., O’Toole, D., Ruszniewski, P., and Wiedenmann, B.
- Published
- 2018
- Full Text
- View/download PDF
11. Students for global oncology: Building a movement for student education and engagement in an emerging field
- Author
-
Vallurupalli, M., primary, Shulman, D.S., additional, Elmore, S.N., additional, Xu, M., additional, Dolisca, S., additional, Ilcisin, L., additional, Judd, A., additional, Kolarova, T., additional, Lock, J., additional, Niu, N., additional, Olsen, M., additional, Taylor, K., additional, Holmer, H., additional, Bhatt, A., additional, and Huang, F., additional
- Published
- 2015
- Full Text
- View/download PDF
12. The Reflective Teaching Model in Biology and Health Instruction for 9th - 12th Grades
- Author
-
Vasilev, V., primary, Hadzhiali, I., additional, and Kolarova, T., additional
- Published
- 2015
- Full Text
- View/download PDF
13. Quantifying the Net Patient Experience Through the First Global Net Patient Survey: a Collaboration Between the International Neuroendocrine Cancer Alliance and Novartis
- Author
-
Kolarova, T., primary, Sissons, M., additional, and Leyden, J., additional
- Published
- 2014
- Full Text
- View/download PDF
14. 515 Therapeutic advantage of chemotherapy drugs in combination with PARP inhibitor PF-01367338 (AG-014699) in human ovarian cancer cells
- Author
-
Ihnen, M., primary, Manivong, K., additional, Chalukya, M., additional, Dering, J., additional, Kolarova, T., additional, Los, G., additional, Christensen, J., additional, Finn, R.S., additional, Slamon, D.S., additional, and Konecny, G.E., additional
- Published
- 2010
- Full Text
- View/download PDF
15. 852 Prediction of response of locally advanced rectal adenocarcinomas to neoadjuvant chemoradiotherapy by microRNA profiling
- Author
-
Svoboda, M., primary, Slaby, O., additional, Fabian, P., additional, Hezova, R., additional, Hrstka, R., additional, Kolarova, T., additional, and Vyzula, R., additional
- Published
- 2010
- Full Text
- View/download PDF
16. The Attitude of 17–18 Years Old Students to Socio-Ethical Issues of Genetic Engineering
- Author
-
Kolarova, T., primary
- Published
- 2009
- Full Text
- View/download PDF
17. Reflective Approach to Studying of Genetics in 9TH-10THGrade
- Author
-
Kolarova, T., primary, Hadjiali, I., additional, and Vasilev, V., additional
- Published
- 2009
- Full Text
- View/download PDF
18. 1164TiP - Quantifying the Net Patient Experience Through the First Global Net Patient Survey: a Collaboration Between the International Neuroendocrine Cancer Alliance and Novartis
- Author
-
Kolarova, T., Sissons, M., and Leyden, J.
- Published
- 2014
- Full Text
- View/download PDF
19. Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey
- Author
-
Jorge Hernando, Teodora Kolarova, Chris Verslype, Gregory Kaltsas, Aude Houchard, Delphine Gueguen, Wouter W. De Herder, Internal Medicine, Institut Català de la Salut, [Hernando J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Kolarova T] International Neuroendocrine Cancer Alliance, Boston, Massachusetts, USA. [Verslype C] University Hospital Gasthuisberg Leuven, Leuven, Belgium. [Kaltsas G] National and Kapodistrian University of Athens, Athens, Greece. [Houchard A, Gueguen D] Ipsen, Boulogne-Billancourt, France. [De Herder WW] Erasmus MC, Rotterdam, The Netherlands, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos [ENFERMEDADES] ,Endocrine and Autonomic Systems ,Otros calificadores::/uso terapéutico [Otros calificadores] ,Endocrinology, Diabetes and Metabolism ,Pacients - Satisfacció ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Tumors neuroendocrins - Tractament ,Somatostatina - Ús terapèutic ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,hormonas, sustitutos de hormonas y antagonistas de hormonas::hormonas::hormonas peptídicas::hormonas hipotalámicas::hormonas inhibidoras de la liberación de hormonas hipofisarias::somatostatina [COMPUESTOS QUÍMICOS Y DROGAS] ,Cellular and Molecular Neuroscience ,Endocrinology ,SDG 3 - Good Health and Well-being ,Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors [DISEASES] ,terapéutica::farmacoterapia::vías de administración de medicamentos::inyecciones [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Other subheadings::/therapeutic use [Other subheadings] ,Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Peptide Hormones::Hypothalamic Hormones::Pituitary Hormone Release Inhibiting Hormones::Somatostatin [CHEMICALS AND DRUGS] ,Therapeutics::Drug Therapy::Drug Administration Routes::Injections [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] - Abstract
Injection experience; Neuroendocrine tumors; Somatostatin analog Experiència en injecció; Tumors neuroendocrins; Anàleg de la somatostatina Experiencia en inyección; Tumores neuroendocrinos; Análogo de la somatostatina Lanreotide autogel/depot (LAN) is a somatostatin analog used in first-line treatment for neuroendocrine tumors (NETs). The aim of HomeLAN was to evaluate the satisfaction with injection experience among patients with NETs receiving at-home LAN injection via patient support programs (PSPs). This was an international, non-interventional, cross-sectional, online survey in adults with NETs enrolled in PSPs, receiving LAN injections at home, administered by a healthcare professional (HCP) or administered independently (self or caregiver administering injection). The primary endpoint was satisfaction with the most recent LAN injection. Secondary endpoints included the level of anxiety prior to injection, impact on daily life, and the extents to which participants felt in control of their life and agreed that home administration met their medical needs. In total, 111 participants from Belgium, Greece, the Netherlands, and Spain completed the survey (50.5% male; mean age, 63.6 years; most common primary tumor site was intestine [47.7%]). For 99 participants, their most recent injection was administered by an HCP. Overall, 95.5% of all participants were satisfied with their most recent injection experience (95% confidence interval: 89.89%–98.06%); 67% reported experiencing no anxiety prior to injection, 91.0% reported that home injection had a “great deal” or “quite a bit” of positive impact on their daily life, and 85.6% strongly agreed that the PSP met their medical needs. In the HCP injection subgroup, 71.7% reported that this mode of administration helped them to feel in control of their lives. In this patient survey, satisfaction levels were high among patients with NETs receiving LAN injections at home via a LAN PSP. Most patients did not experience anxiety prior to their most recent injection and acknowledged that thanks to their treatment they had a good quality of life despite their disease. Most strongly agreed that the PSP met their medical needs, which highlights the valuable service that LAN PSPs provide for patients with NETs. This study was sponsored by Ipsen.
- Published
- 2023
20. Characterization of the AGR2-NPM3 axis uncovers the AGR2 involvement in PD-L1 regulation in colorectal cancer.
- Author
-
Martisova A, Faktor J, Sosolikova T, Klemesova I, Kolarova T, Holcakova J, and Hrstka R
- Subjects
- Humans, Cell Line, Tumor, Nuclear Proteins metabolism, Nuclear Proteins genetics, Colorectal Neoplasms genetics, Colorectal Neoplasms metabolism, Colorectal Neoplasms pathology, Mucoproteins metabolism, Mucoproteins genetics, Oncogene Proteins metabolism, Oncogene Proteins genetics, B7-H1 Antigen metabolism, B7-H1 Antigen genetics, Gene Expression Regulation, Neoplastic, Proteins metabolism, Proteins genetics, Nucleophosmin
- Abstract
Despite extensive research, the molecular role of AGR2 in the progression and metastasis of colorectal cancer (CRC) has not been fully characterized. We used quantitative mass spectrometry (SWATH MS) to identify differentially expressed proteins in paired CRC cell models of the SW480 and SW620 cell lines in response to AGR2 protein level manipulation. Relying on the results from SWATH MS and subsequent immunochemical validation, we selected NMP3 as the top candidate protein associated with AGR2 in CRC tumour cells in our screen. RT‒qPCR and immunochemical analysis confirmed the involvement of AGR2-mediated regulation of NPM3 at the transcriptional and posttranscriptional levels. Since PD-L1 is a constituent of the NPM3 regulatory axis, we aimed to correlate the changes in PD-L1 to the differential expression of AGR2 in our cell models. We found that AGR2 positively regulates PD-L1 levels in both SW480 and SW620 cell lines; additionally, several different CRC patient transcriptome cohorts confirmed the association of AGR2 with PD-L1. Our work reveals a new AGR2-NPM3 regulatory axis and the involvement of AGR2 in the regulation of PD-L1, which paves the way for the association of AGR2 with immune evasion in CRC cells., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
21. CSF neurogranin levels as a biomarker in Alzheimer's disease and frontotemporal lobar degeneration: a cross-sectional analysis.
- Author
-
Jurasova V, Andel R, Katonova A, Veverova K, Zuntychova T, Horakova H, Vyhnalek M, Kolarova T, Matoska V, Blennow K, and Hort J
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Amyloid beta-Peptides cerebrospinal fluid, Apolipoproteins E genetics, Apolipoproteins E cerebrospinal fluid, Cross-Sectional Studies, Neuropsychological Tests, Alzheimer Disease cerebrospinal fluid, Alzheimer Disease diagnosis, Biomarkers cerebrospinal fluid, Cognitive Dysfunction cerebrospinal fluid, Cognitive Dysfunction diagnosis, Frontotemporal Lobar Degeneration cerebrospinal fluid, Frontotemporal Lobar Degeneration diagnosis, Neurogranin cerebrospinal fluid
- Abstract
Background: There is initial evidence suggesting that biomarker neurogranin (Ng) may distinguish Alzheimer's disease (AD) from other neurodegenerative diseases. Therefore, we assessed (a) the discriminant ability of cerebrospinal fluid (CSF) Ng levels to distinguish between AD and frontotemporal lobar degeneration (FTLD) pathology and between different stages within the same disease, (b) the relationship between Ng levels and cognitive performance in both AD and FTLD pathology, and (c) whether CSF Ng levels vary by apolipoprotein E (APOE) polymorphism in the AD continuum., Methods: Participants with subjective cognitive decline (SCD) (n = 33), amnestic mild cognitive impairment (aMCI) due to AD (n = 109), AD dementia (n = 67), MCI due to FTLD (n = 25), and FTLD dementia (n = 29) were recruited from the Czech Brain Aging Study. One-way analysis of covariance (ANCOVA) assessed Ng levels in diagnostic subgroups. Linear regressions evaluated the relationship between CSF Ng levels, memory scores, and APOE polymorphism., Results: Ng levels were higher in aMCI-AD patients compared to MCI-FTLD (F[1, 134] = 15.16, p < .001), and in AD-dementia compared to FTLD-dementia (F[1, 96] = 4.60, p = .029). Additionally, Ng levels were higher in FTLD-dementia patients compared to MCI-FTLD (F[1, 54]= 4.35, p = .034), lower in SCD participants compared to aMCI-AD (F[1, 142] = 10.72, p = .001) and AD-dementia (F[1, 100] = 20.90, p < .001), and did not differ between SCD participants and MCI-FTLD (F[1, 58]= 1.02, p = .491) or FTLD-dementia (F[1, 62]= 2.27, p = .051). The main effect of diagnosis across the diagnostic subgroups on Aβ
1-42 /Ng ratio was significant too (F[4, 263]=, p < .001). We found a non-significant association between Ng levels and memory scores overall (β=-0.25, p = .154) or in AD diagnostic subgroups, and non-significant differences in this association between overall AD APOE ε4 carriers and non-carriers (β=-0.32, p = .358)., Conclusions: In this first study to-date to assess MCI and dementia due to AD or FTLD within one study, elevated CSF Ng appears to be an early biomarker of AD-related impairment, but its role as a biomarker appears to diminish after dementia diagnosis, whereby dementia-related underlying processes in AD and FTLD may begin to merge. The Aβ1-42 /Ng ratio discriminated AD from FTLD patients better than Ng alone. CSF Ng levels were not related to memory in AD or FTLD, suggesting that Ng may be a marker of the biological signs of disease state rather than cognitive deficits., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
22. The Effect of Self-Reported Race on Noninvasive Prenatal Screening Test Characteristics.
- Author
-
Mitra AN, Dingel A, Kolarova T, MacKinnon HJ, Katz R, Lockwood CM, and Shree R
- Abstract
Objective: Low fetal fraction (FF) on cell-free DNA (cfDNA)-based noninvasive prenatal screening (NIPS) is a common etiology for indeterminate results. As maternal Black race is implicated as a risk factor for low FF and more indeterminate results, we sought to evaluate this association., Study Design: This was a single-institution, retrospective cohort study of cfDNA-based NIPS performed between May 2017 and May 2022 with complete clinical data abstraction. We compared FF, indeterminate rates, and total cfDNA concentration among self-reported Black, White, and Other groups from NIPS results from 2017 to 2022 with full clinical data abstraction. Using linear regression and interaction testing, we evaluated associations between self-reported race, FF, indeterminate rate, and total cfDNA concentration., Results: In total, 1,591 participants met the inclusion criteria; 70.8% ( n = 1,126) self-identified as White, 6.9% ( n = 110) as Black, and 22.3% ( n = 355) self-identified with another race. Mean FF was not different between the White, Black, or Other groups (11.8 vs. 11.2 vs. 11.7%, respectively, p = 0.52). This remained true after adjusting for body mass index (BMI), gestational age (GA) at draw, and fetal sex (all p > 0.17). Interaction testing for FF and total cfDNA by race with BMI, GA at draw, and fetal sex demonstrated no effect modification., Conclusion: In our population, maternal self-identified race, particularly Black race, does not affect FF. Biological plausibility for race-based differences on clinical tests requires ongoing thoughtful consideration., Key Points: · NIPS is widely used to screen for fetal aneuploidy.. · FF is an important test metric, and low FF is associated with adverse outcomes, like aneuploidy.. · In existing studies, Black race is implicated as a risk factor for lower FF.. · Our study found no differences in FF between groups by self-reported race.. · Biological plausibility for race-based differences on clinical tests requires ongoing consideration.., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. Small change - big consequence: The impact of C15-C16 double bond in a D‑ring of estrone on estrogen receptor activity.
- Author
-
Vonka P, Rarova L, Bazgier V, Tichy V, Kolarova T, Holcakova J, Berka K, Kvasnica M, Oklestkova J, Kudova E, Strnad M, and Hrstka R
- Subjects
- Humans, Female, Fulvestrant pharmacology, Fulvestrant therapeutic use, Receptors, Estrogen metabolism, Molecular Docking Simulation, Cell Line, Tumor, Tamoxifen pharmacology, Estrogen Receptor alpha genetics, Estrogen Receptor alpha metabolism, Estradiol pharmacology, Estradiol therapeutic use, Estrone pharmacology, Breast Neoplasms drug therapy, Breast Neoplasms metabolism
- Abstract
Estrogen receptor alpha (ER) is a key biomarker for breast cancer, and the presence or absence of ER in breast and other hormone-dependent cancers decides treatment regimens and patient prognosis. ER is activated after ligand binding - typically by steroid. 2682 steroid compounds were used in a molecular docking study to identify novel ligands for ER and to predict compounds that may show anticancer activity. The effect of the most promising compounds was determined by a novel luciferase reporter assay. Two compounds, 7 and 12, showing ER inhibitory activity comparable to clinical inhibitors such as tamoxifen or fulvestrant were selected. We propose that the inhibitory effect of compounds 7 and 12 on ER is related to the presence of a double bond in their D-ring, which may protect against ER activation by reducing the electron density of the keto group, or may undergo metabolism leading to an active compound. Western blotting revealed that compound 12 decreased the level of ER in the breast cancer cell line MCF7, which was associated with reduced expression of both isoforms of the progesterone receptor, a well-known downstream target of ER. However, compound 12 has a different mechanism of action from fulvestrant. Furthermore, we found that compound 12 interferes with mitochondrial functions, probably by disrupting the electron transport chain, leading to induction of the intrinsic apoptotic pathway even in ER-negative breast cancer cells. In conclusion, the combination of computational and experimental methods shown here represents a rapid approach to determine the activity of compounds towards ER. Our data will not only contribute to research focused on the regulation of ER activity but may also be useful for the further development of novel steroid receptor-targeted drugs applicable in clinical practice., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours.
- Author
-
Jørgensen JOL, de Herder WW, Martin WA, Kolarova T, Marks M, Follin C, Geilvoet W, and Melmed S
- Subjects
- Humans, Somatostatin therapeutic use, Receptors, Somatostatin therapeutic use, Ligands, Pain drug therapy, Acromegaly drug therapy, Neuroendocrine Tumors drug therapy
- Abstract
Introduction: People living with acromegaly and neuroendocrine tumours (NETs) may be treated with injectable somatostatin receptor ligands (SRLs), administered by either a caregiver or as self-injection via a proprietary or generic device. Injection device attributes that contribute to ease of use and storage, minimise preparation requirements, and reduce injection pain are associated with improved adherence and more favourable therapeutic outcomes. The aim of this study was to assess current opinion surrounding favourable SRL device attributes for people living with acromegaly and NETs as well as that of their caregivers., Methods: Participants (healthcare professionals [HCPs] and patients/non-HCP caregivers) from 11 countries were invited to answer survey questions related to their demographic, experience, and preferences as they relate to the real-world use of injectable SRL devices. Questions were developed based on review of available literature and meetings with a Scientific Committee., Results: Device attributes preferred by the patient/non-HCP caregiver group (n = 211) included confidence that the correct drug amount is delivered (76%), quick administration with minimal pain/discomfort (68%), and device safety (needle-safety and low risk of contamination; 53%). Device attributes preferred by HCPs (n = 52) were quick administration with minimal pain/discomfort (69%), correct use is easy to learn, confidence in handling the device (63%), and confidence that the correct drug amount is delivered (62%)., Conclusion: The results identified key features of injection devices for SRL therapy which merit consideration for optimal management and underscore the importance of patient partnership in treatment decisions., (© 2023. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
25. In Reply.
- Author
-
Burns RN, Kolarova T, Katz R, Ma K, and Delaney S
- Abstract
Competing Interests: Financial Disclosure The authors did not report any potential conflicts of interest.
- Published
- 2023
- Full Text
- View/download PDF
26. Global challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients.
- Author
-
Dureja S, McDonnell M, Van Genechten D, Bouvier C, Kolarova T, O'Toole D, Singh H, Chen J, Howe J, Singh S, Rodien-Louw C, Leyden S, Gellerman E, Herman J, and Pavel M
- Subjects
- Humans, Positron Emission Tomography Computed Tomography, Octreotide, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors therapy, Neuroendocrine Tumors metabolism, Organometallic Compounds
- Abstract
SCAN, an online survey, measured access to diagnosis, treatments and monitoring of neuroendocrine tumor (NET) patients globally. Between September and November 2019, NET patients and healthcare professionals (HCPs) completed an online, semi-standardized survey with 54 patient questions and 33 HCP questions. A total of 2359 patients with NETs and 436 HCPs responded. Misdiagnosis was common (44% [1043/2359]). Mean time to diagnosis was 4.8 years (standard deviation [SD], 6.2). Compared with global figures (60% [1407/2359]), the availability of
68 Ga-DOTA positron emission tomography (PET)/computed tomography (CT) was significantly lower in Asia (45% [126/280]) and higher in Oceania (86% [171/200]). HCPs reported that68 Ga-DOTA PET/CT was free/affordable to fewer patients in Emerging and Developing Economies (EDE) than Advanced Economies (AE; 17% [26/150] and 59% [84/142], respectively). Compared with global data (52% [1234/2359]), patient-reported availability of peptide receptor radionuclide therapy (PRRT) was significantly lower in Asia (31% [88/280]) and higher in Oceania (61% [122/200]). Significant differences were observed in average annual NET specialist costs between AE and EDE ($1081 and $2915, respectively). Compared with AE, patients in EDE traveled further for NET specialists (1032 [SD, 1578] and 181 [SD, 496] km, respectively). Patients and HCPs both recommended referral to HCPs that were more knowledgeable in the field of NETs and had better access to NET experts/specialist centers. National care pathways, enhancing HCP NET knowledge and ensuring effective diagnostics and access to appropriate treatments are crucial to improving patient survival and NET care worldwide., (© 2023 The International Neuroendocrine Cancer Alliance. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.)- Published
- 2023
- Full Text
- View/download PDF
27. Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey.
- Author
-
Hernando J, Kolarova T, Verslype C, Kaltsas G, Houchard A, Gueguen D, and De Herder WW
- Subjects
- Adult, Humans, Male, Middle Aged, Female, Cross-Sectional Studies, Quality of Life, Patient Satisfaction, Neuroendocrine Tumors pathology
- Abstract
Lanreotide autogel/depot (LAN) is a somatostatin analog used in first-line treatment for neuroendocrine tumors (NETs). The aim of HomeLAN was to evaluate the satisfaction with injection experience among patients with NETs receiving at-home LAN injection via patient support programs (PSPs). This was an international, non-interventional, cross-sectional, online survey in adults with NETs enrolled in PSPs, receiving LAN injections at home, administered by a healthcare professional (HCP) or administered independently (self or caregiver administering injection). The primary endpoint was satisfaction with the most recent LAN injection. Secondary endpoints included the level of anxiety prior to injection, impact on daily life, and the extents to which participants felt in control of their life and agreed that home administration met their medical needs. In total, 111 participants from Belgium, Greece, the Netherlands, and Spain completed the survey (50.5% male; mean age, 63.6 years; most common primary tumor site was intestine [47.7%]). For 99 participants, their most recent injection was administered by an HCP. Overall, 95.5% of all participants were satisfied with their most recent injection experience (95% confidence interval: 89.89%-98.06%); 67% reported experiencing no anxiety prior to injection, 91.0% reported that home injection had a "great deal" or "quite a bit" of positive impact on their daily life, and 85.6% strongly agreed that the PSP met their medical needs. In the HCP injection subgroup, 71.7% reported that this mode of administration helped them to feel in control of their lives. In this patient survey, satisfaction levels were high among patients with NETs receiving LAN injections at home via a LAN PSP. Most patients did not experience anxiety prior to their most recent injection and acknowledged that thanks to their treatment they had a good quality of life despite their disease. Most strongly agreed that the PSP met their medical needs, which highlights the valuable service that LAN PSPs provide for patients with NETs., (© 2023 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.)
- Published
- 2023
- Full Text
- View/download PDF
28. Increased fetal microchimerism in immune and stem cell subsets in preeclampsia.
- Author
-
McCartney SA, Kolarova T, Kanaan SB, Chae A, Laughney CI, Nelson JL, Gammill HS, and Shree R
- Subjects
- Pregnancy, Female, Humans, Chimerism, Fetus, Stem Cells, Leukocytes, Mononuclear, Pre-Eclampsia
- Abstract
Problem: Preeclampsia (PE) is associated with an increased risk of maternal cardiovascular disease (CVD), however, it is unclear whether this is due to shared underlying physiology or changes which occur during the disease process. Fetal microchimerism (FMc) within the maternal circulation can durably persist decades after pregnancy, is known to occur at greater frequency in PE, and can potentially affect local and systemic immune programming, thus changes in cellular FMc may provide a mechanism for long-term health outcomes associated with PE., Method of Study: We investigated whether PE is associated with alterations in FMc immune and stem cell populations. We analyzed maternal peripheral blood mononuclear cells (PBMC) from PE cases (n = 16) and matched controls from normal pregnancies (n = 16), from which immune and stem cell subsets were isolated by flow cytometry. Genomic DNA was extracted from total PMBC and individual cell subsets, and FMc frequency was quantified by quantitative polymerase chain reaction assays targeting a fetal-specific non-shared polymorphism identified from family genotyping., Results: There was a significant increase in FMc concentration in immune cell subsets in PE cases compared to controls, predominantly in B cell, and NK cell lymphocyte populations. There was no significant difference in FMc frequency or concentration within the stem cell population between PE and controls., Conclusions: The altered concentrations of immune cells within FMc in the maternal blood provides a potential mechanism for the inflammation which occurs during PE to induce long-lasting changes to the maternal immune system and may potentially promote chronic maternal disease., (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
29. Reconsidering Race Adjustment in Prenatal Alpha-Fetoprotein Screening.
- Author
-
Burns RN, Kolarova T, Katz R, Ma K, and Delaney S
- Subjects
- Pregnancy, Female, Humans, Infant, Retrospective Studies, alpha-Fetoproteins analysis, Prenatal Diagnosis
- Abstract
Objective: Black racial designation is the only race for which adjustment is recommended for maternal prenatal serum alpha-fetoprotein (AFP) screening. The objective of this study is to reevaluate the relationship between maternal race and maternal serum AFP values in prenatal analyte screening., Methods: This was a single-center retrospective analysis of patients who underwent prenatal analyte screening between January 2007 and December 2020. Nomograms for raw maternal serum AFP values by gestational age were created and compared between patients identified as "Black" and "non-Black" on the laboratory requisition. Multivariable linear regression models were created to evaluate the relationship among gestational age, maternal weight, and maternal race on maternal serum AFP levels. The new models were compared with the laboratory-derived calculations, which used historically determined race adjustments., Results: A total of 43,997 patients underwent analyte screening, and 27,710 patients had complete data for analysis. Of these, 6% were identified as Black. Black patients had laboratory blood draws at a mean gestational age of 123 days, compared with 120 days in non-Black patients ( P <.001), and had higher maternal weight (mean 170 vs 161 lbs, P <.001). Nomograms for raw maternal serum AFP values did not differ between Black and non-Black patients ( P =.065). When adjusted for gestational age and maternal weight, no difference in maternal serum AFP values was identified between Black and non-Black individuals ( P =.81)., Conclusion: No difference in maternal serum AFP values was identified between Black and non-Black pregnant individuals when adjusted by maternal weight and gestational age at blood draw. These findings suggest that routine race-based adjustment of maternal serum AFP screening should be discontinued., Competing Interests: Financial Disclosure The authors did not report any potential conflicts of interest., (Copyright © 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
30. European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission.
- Author
-
Lawler M, Davies L, Oberst S, Oliver K, Eggermont A, Schmutz A, La Vecchia C, Allemani C, Lievens Y, Naredi P, Cufer T, Aggarwal A, Aapro M, Apostolidis K, Baird AM, Cardoso F, Charalambous A, Coleman MP, Costa A, Crul M, Dégi CL, Di Nicolantonio F, Erdem S, Geanta M, Geissler J, Jassem J, Jagielska B, Jonsson B, Kelly D, Kelm O, Kolarova T, Kutluk T, Lewison G, Meunier F, Pelouchova J, Philip T, Price R, Rau B, Rubio IT, Selby P, Južnič Sotlar M, Spurrier-Bernard G, van Hoeve JC, Vrdoljak E, Westerhuis W, Wojciechowska U, and Sullivan R
- Subjects
- Humans, Pandemics, Health Services Research, Europe epidemiology, Europe, Eastern, COVID-19 epidemiology, Neoplasms diagnosis, Neoplasms epidemiology, Neoplasms therapy
- Abstract
Cancer research is a crucial pillar for countries to deliver more affordable, higher quality, and more equitable cancer care. Patients treated in research-active hospitals have better outcomes than patients who are not treated in these settings. However, cancer in Europe is at a crossroads. Cancer was already a leading cause of premature death before the COVID-19 pandemic, and the disastrous effects of the pandemic on early diagnosis and treatment will probably set back cancer outcomes in Europe by almost a decade. Recognising the pivotal importance of research not just to mitigate the pandemic today, but to build better European cancer services and systems for patients tomorrow, the Lancet Oncology European Groundshot Commission on cancer research brings together a wide range of experts, together with detailed new data on cancer research activity across Europe during the past 12 years. We have deployed this knowledge to help inform Europe's Beating Cancer Plan and the EU Cancer Mission, and to set out an evidence-driven, patient-centred cancer research roadmap for Europe. The high-resolution cancer research data we have generated show current activities, captured through different metrics, including by region, disease burden, research domain, and effect on outcomes. We have also included granular data on research collaboration, gender of researchers, and research funding. The inclusion of granular data has facilitated the identification of areas that are perhaps overemphasised in current cancer research in Europe, while also highlighting domains that are underserved. Our detailed data emphasise the need for more information-driven and data-driven cancer research strategies and planning going forward. A particular focus must be on central and eastern Europe, because our findings emphasise the widening gap in cancer research activity, and capacity and outcomes, compared with the rest of Europe. Citizens and patients, no matter where they are, must benefit from advances in cancer research. This Commission also highlights that the narrow focus on discovery science and biopharmaceutical research in Europe needs to be widened to include such areas as prevention and early diagnosis; treatment modalities such as radiotherapy and surgery; and a larger concentration on developing a research and innovation strategy for the 20 million Europeans living beyond a cancer diagnosis. Our data highlight the important role of comprehensive cancer centres in driving the European cancer research agenda. Crucial to a functioning cancer research strategy and its translation into patient benefit is the need for a greater emphasis on health policy and systems research, including implementation science, so that the innovative technological outputs from cancer research have a clear pathway to delivery. This European cancer research Commission has identified 12 key recommendations within a call to action to reimagine cancer research and its implementation in Europe. We hope this call to action will help to achieve our ambitious 70:35 target: 70% average 10-year survival for all European cancer patients by 2035., Competing Interests: Declaration of interests ML declares honoraria from Bayer, Carnall Farrar, EMD Serono, Novartis, Pfizer, and Roche unrelated to this work and membership of the board of the European Cancer Organisation (ECO). AA declares Advanced NIH Fellowship unrelated to this work. AMB declares honorarium from Roche unrelated to this work and Presidency of Lung Cancer Europe. MC declares membership of the board of ECO and the European Society of Oncology Pharmacy. FC declares consultancy and advisory board membership of Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck-Sharp, Merus, Mylan, Mundipharma, Novartis, Pfizer, PierreFabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, and Touchime unrelated to this work. TC declares honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, Merck Sharpe & Dohme, Pfizer, and Takeda unrelated to this work. LD declares consultancy from the International Cancer Research Partnership unrelated to this work. FDN declares grants from the AIRC Foundation for Cancer Research, Associazione Italiana per la Ricerca sul Cancro, and Fondazione Piemontese per la Ricerca sul Cancro-ONLUS, and consultancy from Pierre Fabre unrelated to this work. JJ declares consultancy from AstraZeneca, Exact Sciences, and Merck Sharpe & Dohme unrelated to this work. DK declares honoraria from Merck Sharpe & Dohme unrelated to this work. TKo declares grants from Ipsen, AAA Pharma, Novartis, Isotope Technologies Munich, Victory Net Foundation, and Camulus, and honoraria or support from Cor2Ed, Ipsen, ECO, International Cancer Genome Consortium unrelated to this work. CLV received support from AIRC Foundation. YL is chair of the HERO VBHC and member of the European Society for Radiotherapy and Oncology (ESTRO) Scientific Committee, the Belgian College of Oncology, and a personal investigator on the European Organization for Research and Treatment of Cancer/ESTRO E2-RADIATE project. PS declares support from ECO and the European School of Oncology. SO, KO, AS, CA, PN, KA, MA, AC, MPC, ACo, CLD, AE, SE, MG, BJo, OK, TKu, GL, FM, JP, TP, RP, BR, ITR, MJS, GSB, JVH, EV, WW, UW, and RS declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
31. European Cancer Organisation's Inequalities Network: Putting Cancer Inequalities on the European Policy Map.
- Author
-
Van Poppel H, Battisti NML, Lawler M, Kolarova T, Daly J, Rizvi K, Greene R, Buyens G, Oliver K, Price R, Osmanovic N, and Venegoni E
- Subjects
- Humans, Neoplasms epidemiology, Neoplasms therapy, Policy
- Abstract
Competing Interests: Nicolo Matteo Luca BattistiConsulting or Advisory Role: Pfizer, Sanofi, Abbott NutritionSpeakers' Bureau: Pfizer, AbbVie, SanofiTravel, Accommodations, Expenses: Pfizer, Genomic Health, Lilly Mark LawlerHonoraria: Pfizer, Roche, Bayer Health, NovartisTravel, Accommodations, Expenses: Pfizer, Roche Katie RizviHonoraria: Roche Robert GreeneConsulting or Advisory Role: GlaxoSmithKline Kathy OliverConsulting or Advisory Role: Bristol Myers Squibb (Inst), Seattle Genetics (Inst), Novartis Italy (Inst), Sanofi/Regeneron (Inst), Novocure (Inst), Eisai (Inst)Other Relationship: Bristol Myers Squibb (Inst), Novocure (Inst), Photonamic (Inst), Bayer (Inst), Northwest Biotherapeutics (Inst), Novartis (Inst), Elekta (Inst), Medac (Inst), GW Pharmaceuticals (Inst), Pfizer (Inst), Karyopharm Therapeutics (Inst), Apogenix (Inst)No other potential conflicts of interest were reported.
- Published
- 2022
- Full Text
- View/download PDF
32. Identification of AGR2 Gene-Specific Expression Patterns Associated with Epithelial-Mesenchymal Transition.
- Author
-
Martisova A, Sommerova L, Krejci A, Selingerova I, Kolarova T, Zavadil Kokas F, Holanek M, Podhorec J, Kazda T, and Hrstka R
- Subjects
- Arachidonic Acid, Cell Line, Tumor, Cell Movement genetics, Cyclooxygenase 2 genetics, Prostaglandins E, Transforming Growth Factor beta genetics, Vinculin genetics, Epithelial-Mesenchymal Transition genetics, Gene Expression Regulation, Neoplastic
- Abstract
The TGF-β signaling pathway is involved in numerous cellular processes, and its deregulation may result in cancer development. One of the key processes in tumor progression and metastasis is epithelial to mesenchymal transition (EMT), in which TGF-β signaling plays important roles. Recently, AGR2 was identified as a crucial component of the cellular machinery responsible for maintaining the epithelial phenotype, thereby interfering with the induction of mesenchymal phenotype cells by TGF-β effects in cancer. Here, we performed transcriptomic profiling of A549 lung cancer cells with CRISPR-Cas9 mediated AGR2 knockout with and without TGF-β treatment. We identified significant changes in transcripts associated with focal adhesion and eicosanoid production, in particular arachidonic acid metabolism. Changes in transcripts associated with the focal adhesion pathway were validated by RT-qPCR of COL4A1 , COL4A2 , FLNA , VAV3 , VEGFA , and VINC mRNAs. In addition, immunofluorescence showed the formation of stress fibers and vinculin foci in cells without AGR2 and in response to TGF-β treatment, with synergistic effects observed. These findings imply that both AGR2 downregulation and TGF-β have a role in focal adhesion formation and cancer cell migration and invasion. Transcripts associated with arachidonic acid metabolism were downregulated after both AGR2 knockout and TGF-β treatment and were validated by RT-qPCR of GPX2 , PTGS2 , and PLA2G4A . Since PGE
2 is a product of arachidonic acid metabolism, its lowered concentration in media from AGR2 -knockout cells was confirmed by ELISA. Together, our results demonstrate that AGR2 downregulation and TGF-β have an essential role in focal adhesion formation; moreover, we have identified AGR2 as an important component of the arachidonic acid metabolic pathway., Competing Interests: The authors declare no conflict of interest.- Published
- 2022
- Full Text
- View/download PDF
33. Co-creating with patients an impact framework across the medicine's life cycle: a qualitative study exploring patients' experiences of involvement in and perceptions of impact measures.
- Author
-
Gorbenko O, Cavillon P, Giles RH, Kolarova T, Marks M, Cardone A, Bagga S, and Nolan C
- Abstract
Background: The biopharmaceutical industry is challenged with efficiently delivering medicines that patients truly value. This can be addressed by engaging patients and caregivers throughout a medicine's life cycle, ensuring that products meet the needs and expectations of those who take them. While isolated best practice examples of patient engagement exist, they remain relatively ad hoc and not fully embedded within Research & Development (R&D) practices. To encourage more patient engagement, the 'impact' of patient engagement projects (PEP) must be objectively measured and demonstrated. Some frameworks have been proposed; however, there is no evidence of widespread adoption, nor have patients' perspectives been robustly explored. The objective of this qualitative study was therefore to understand patients' perspectives of impact measurement that can be systematically applied within a biopharmaceutical company., Methods: Semi-structured interviews were conducted with 13 patient organisation (PO) representatives exploring their experiences of engagement and reflections on 23 candidate patient engagement impact measures categorised into five groups: Medicines R&D Priorities; Clinical Trial Design; Regulatory & Market Access Submissions; Product Support & Information; and Disease Support & Information. Thematic analysis was undertaken and impact measures revised in line with interview participant feedback. Emerging themes and revisions to impact measures were validated at a joint workshop with 4 patient advisors representing 4 POs., Results: The study revealed that PO representatives feel a deep sense of accomplishment and ownership when collaborating on PEPs with biopharmaceutical companies. They largely conceptualise 'impact' as positive, tangible and useful outcomes. The revisions made to the pre-defined patient engagement impact measures fell into three broad categories: (1) a requirement for greater context; (2) capturing the nature of patient influence; and (3) terminology changes. The greatest number of revisions concerned 'requiring greater context', for example, including additional descriptions, patient quotes, and satisfaction., Conclusions: This study sheds light on how patient advocates view 'impact'. Typically this means delivering 'value' important for them. Therefore, the authors of this paper created the term 'value-impact' to comprehensively characterise this conceptualisation, and propose a value-impact measurement plan, incorporating longitudinal data. Through this understanding and in light of other recently published work, wide-scale adoption and implementation of the measurement of value-impact across the biopharmaceutical industry can be realised., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
34. First evidence of long-term effects of transcranial pulse stimulation (TPS) on the human brain.
- Author
-
Matt E, Kaindl L, Tenk S, Egger A, Kolarova T, Karahasanović N, Amini A, Arslan A, Sariçiçek K, Weber A, and Beisteiner R
- Subjects
- Diffusion Magnetic Resonance Imaging, Humans, Magnetic Resonance Imaging methods, Brain, Somatosensory Cortex physiology
- Abstract
Background: With the high spatial resolution and the potential to reach deep brain structures, ultrasound-based brain stimulation techniques offer new opportunities to non-invasively treat neurological and psychiatric disorders. However, little is known about long-term effects of ultrasound-based brain stimulation. Applying a longitudinal design, we comprehensively investigated neuromodulation induced by ultrasound brain stimulation to provide first sham-controlled evidence of long-term effects on the human brain and behavior., Methods: Twelve healthy participants received three sham and three verum sessions with transcranial pulse stimulation (TPS) focused on the cortical somatosensory representation of the right hand. One week before and after the sham and verum TPS applications, comprehensive structural and functional resting state MRI investigations and behavioral tests targeting tactile spatial discrimination and sensorimotor dexterity were performed., Results: Compared to sham, global efficiency significantly increased within the cortical sensorimotor network after verum TPS, indicating an upregulation of the stimulated functional brain network. Axial diffusivity in left sensorimotor areas decreased after verum TPS, demonstrating an improved axonal status in the stimulated area., Conclusions: TPS increased the functional and structural coupling within the stimulated left primary somatosensory cortex and adjacent sensorimotor areas up to one week after the last stimulation. These findings suggest that TPS induces neuroplastic changes that go beyond the spatial and temporal stimulation settings encouraging further clinical applications., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
35. The Role of Patient Support Groups in Neuroendocrine Neoplasms.
- Author
-
Kolarova T and Bouvier C
- Subjects
- Empathy, Humans, Neuroendocrine Tumors therapy, Patient Advocacy, Patient Education as Topic, Health Communication, Neuroendocrine Tumors psychology, Patient-Centered Care methods, Quality of Life psychology, Self-Help Groups
- Abstract
Purpose of Review: The purpose of this review is to establish the role patient support groups play in NENs., Recent Findings: Published data on the role and work done by these groups is extremely sparse, so the review references publications in the wider cancer advocacy context. For the purposes of the review, a survey was carried out among the members of a global umbrella organization to ascertain the level of activities undertaken in support of the NEN patient community. The concept of "support groups" has changed significantly, as these groups have evolved from patient peer-to-peer support provision to a strategic focus on improving awareness and education among all stakeholders, generating patient evidence to influence policies for access to optimal diagnostics, treatment, and care, and setting the research agenda. Today, NEN patient organizations have an instrumental role of catalysts of change across the healthcare spectrum-especially relevant in a setting of less common and not well-understood diseases, where clear pathways and guidelines are still a challenge.
- Published
- 2021
- Full Text
- View/download PDF
36. Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era.
- Author
-
Rodriguez-Freixinos V, Capdevila J, Pavel M, Thawer A, Baudin E, O'Toole D, Herrmann K, Welin S, Grozinsky-Glasberg S, de Herder WW, Valle JW, Herman J, Kolarova T, Bouvier C, Falconi M, Ferone D, and Singh S
- Subjects
- Carcinoid Tumor diagnosis, Consensus, Gastrointestinal Neoplasms diagnosis, Humans, Pancreatic Neoplasms diagnosis, Thoracic Neoplasms diagnosis, COVID-19, Carcinoid Tumor therapy, Gastrointestinal Neoplasms therapy, Medical Oncology standards, Pancreatic Neoplasms therapy, Thoracic Neoplasms therapy
- Abstract
Neuroendocrine neoplasms (NENs) are a heterogeneous family of uncommon tumours with challenging diagnosis, clinical management and unique needs that almost always requires a multidisciplinary approach. In the absence of guidance from the scientific literature, along with the rapidly changing data available on the effect of COVID-19, we report how 12 high-volume NEN centres of expertise in 10 countries at different stages of the evolving COVID-19 global pandemic along with members of international neuroendocrine cancer patient societies have suggested to preserve high standards of care for patients with NENs. We review the multidisciplinary management of neuroendocrine neoplasms during the COVID-19 pandemic, and we suggest potential strategies to reduce risk and aid multidisciplinary treatment decision-making. By sharing our joint experiences, we aim to generate recommendations for proceeding to other institutions facing the same challenges., Competing Interests: Conflict of interest statement Ms. Kolarova reports grants from Novartis Pharmaceuticals Corporation, grants from Advanced Accelerator Applications SA, grants from IPSEN PHARMA, grants from ITM Isotopen Technologien. Munchen AG, during the conduct of the study; grants from Novartis Pharmaceuticals Corporation, grants from Advanced Accelerator Applications SA, grants from IPSEN PHARMA, grants from ITM. Isotopen Technologien Munchen AG, outside the submitted work. Dr. Valle reports personal fees from Agios, personal fees from AstraZeneca, personal fees from Debiopharm, personal fees from Delcath Systems, personal fees from Genoscience Pharma, personal fees from Imaging Equipment Limited, personal fees from Incyte, personal fees from Ipsen, personal fees from Keocyt, personal fees from Merck, personal fees from Mundipharma EDO, personal fees from Novartis, grants, personal fees and non-financial support from NuCana, personal fees from PCI Biotech, personal fees from Pieris Pharmaceuticals, and personal fees and non-financial support from Pfizer, personal. Dr. de Herder reports grants from Ipsen, personal fees from Ipsen, personal fees from Novartis, personal fees from Pfizer,and personal fees from AAA, outside the submitted work. Ken Herrmann reports personal fees from Bayer, other from Sofie Biosciences, personal fees from SIRTEX, other from ABX, personal fees and non-financial support from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees and non-financial support from Siemens Healthineers, non-financial support from GE Healthcare, personal fees from Astellas, and personal fees from yMabs, all outside the submitted work. Dr. Capdevila reports grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Ipsen, personal fees from Exelixis, grants and personal fees from Bayer, grants and personal fees from Eisai, grants and personal fees from Advanced Accelerator Applications, personal fees from Lilly, personal fees from Sanofi, personal fees from Merck Serono, grants from Astrazeneca, outside the submitted work. Dr. Pavel reports other from Novartis, personal fees from AAA, personal fees and other from IPSEN, personal fees from Riemser, other from ITM, during the conduct of the study. Dr. Thawer reports grants from Novartis, other from Novartis, other from Pfizer, other from Abbvie, grants from AstraZeneca, outside the submitted work. Dr. Singh reports other relationships with Pfizer and Ipsen/Novartis, outside the submitted work. Remaining authors declare no conflicts of interest., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
37. Transient commensal clonal interactions can drive tumor metastasis.
- Author
-
Naffar-Abu Amara S, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, Kuhn EP, Kolarova T, Hage C, Ganesh K, Panayiotou R, Foster R, Rueda BR, Aktipis A, Spellman P, Ince TA, Xiu J, Oberley M, Gatalica Z, Navin N, Mills GB, Bronson RT, and Brugge JS
- Subjects
- Amphiregulin metabolism, Animals, Ascites pathology, Carcinogenesis pathology, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell pathology, Cell Line, Tumor, Cell Proliferation, Cell Separation, Cohort Studies, DNA Copy Number Variations genetics, Epithelium pathology, Female, Gene Amplification, Humans, Kidney Neoplasms genetics, Kidney Neoplasms pathology, Ligands, Mice, SCID, Models, Biological, Peritoneal Neoplasms secondary, Phenotype, Receptor, ErbB-2 genetics, Time Factors, Cell Communication, Clone Cells pathology, Neoplasm Metastasis pathology
- Abstract
The extent and importance of functional heterogeneity and crosstalk between tumor cells is poorly understood. Here, we describe the generation of clonal populations from a patient-derived ovarian clear cell carcinoma model which forms malignant ascites and solid peritoneal tumors upon intraperitoneal transplantation in mice. The clonal populations are engineered with secreted Gaussia luciferase to monitor tumor growth dynamics and tagged with a unique DNA barcode to track their fate in multiclonal mixtures during tumor progression. Only one clone, CL31, grows robustly, generating exclusively malignant ascites. However, multiclonal mixtures form large solid peritoneal metastases, populated almost entirely by CL31, suggesting that transient cooperative interclonal interactions are sufficient to promote metastasis of CL31. CL31 uniquely harbors ERBB2 amplification, and its acquired metastatic activity in clonal mixtures is dependent on transient exposure to amphiregulin, which is exclusively secreted by non-tumorigenic clones. Amphiregulin enhances CL31 mesothelial clearance, a prerequisite for metastasis. These findings demonstrate that transient, ostensibly innocuous tumor subpopulations can promote metastases via "hit-and-run" commensal interactions.
- Published
- 2020
- Full Text
- View/download PDF
38. Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals.
- Author
-
Leyden S, Kolarova T, Bouvier C, Caplin M, Conroy S, Davies P, Dureja S, Falconi M, Ferolla P, Fisher G, Goldstein G, Hicks RJ, Lawrence B, Majima Y, Metz DC, O'Toole D, Ruszniewski P, Wiedenmann B, and Hollander R
- Subjects
- Adolescent, Adult, Global Burden of Disease, Health Communication, Health Personnel statistics & numerical data, Humans, Incidence, Information Seeking Behavior, Medical Oncology organization & administration, Medical Oncology statistics & numerical data, Middle Aged, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors epidemiology, Neuroendocrinology organization & administration, Neuroendocrinology statistics & numerical data, Patient Advocacy statistics & numerical data, Prevalence, Professional-Patient Relations, Surveys and Questionnaires statistics & numerical data, Young Adult, Global Health, Health Services Needs and Demand statistics & numerical data, Neuroendocrine Tumors therapy, Patient Participation statistics & numerical data, Professional Practice Gaps statistics & numerical data
- Abstract
Due to the increasing incidence and prevalence of neuroendocrine tumors (NETs), there is a need to assess any gaps in awareness and care. A survey was undertaken in 2017 to identify perceived unmet needs from the perspectives of patients/families, patient advocates and health care professionals (HCPs). The survey consisted of 33-37 questions (depending on type of respondent) across four areas: information, care, treatments and research. In total, 443 participants from 26 countries responded: 338 patients/families, 35 advocates and 70 HCPs. Perceived unmet needs regarding provision of information at diagnosis differed between groups. While 59% of HCPs believed they provided sufficient information, informational needs were mostly/fully met for only 30% of patients and 18% of advocates. Additionally, 91% of patients and 97% of advocates felt that patients had to search for information themselves. Availability of Gallium-68-Dotatate PET/CT scan was limited for the majority of patients (patients: 73%; advocates: 85%; HCP: 86%), as was access to treatments, particularly peptide receptor radionuclide therapy (patients: 42%; advocates: 95%; HCPs: 77%). All groups felt that standards of care, including psychological needs and diagnosis of mental health, were not fully met. Although about two-thirds of patients were managed by a multidisciplinary team, 14% of patients reportedly did not have enough contact. All groups supported more patient involvement in research; patients and advocates prioritized improvement in diagnosis and HCPs focused on clinical trials. This survey revealed significant unmet needs but differing perceptions regarding these among the groups. There is a need for investigation and collaboration to improve standards of care for NET patients., (© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
- Published
- 2020
- Full Text
- View/download PDF
39. Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States.
- Author
-
Wolin EM, Leyden J, Goldstein G, Kolarova T, Hollander R, and Warner RRP
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Neuroendocrine Tumors pathology, Self Report, United States, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors therapy, Surveys and Questionnaires, Tumor Burden
- Abstract
Objectives: The aim of this survey was to examine the experience of patients with neuroendocrine tumors (NETs) to raise awareness of the NET-related burden and identify unmet needs. Here, we report data from patients in the United States., Methods: Patients with NETs participated in a 25-minute anonymous survey, conducted primarily online from February to May 2014. Survey questions captured information on sociodemographics, clinical characteristics, NET diagnostic experience, disease impact/management, interaction with medical teams, and NETs knowledge/awareness., Results: Of 1928 patients who participated globally, the largest percentage was from the United States (39%). Approximately 50% of US patients reported being diagnosed with other conditions before receiving their NET diagnosis, which for 34% took 5 years or more. Patients experienced many symptoms on a daily basis as a result of NETs, which had a substantial negative impact on their work and daily lives. Numerous improvements were suggested by patients, including better access to NET-specific treatments and medical teams/centers and better education for the management of disease-related and treatment-related symptoms., Conclusions: This survey demonstrated the significant burden of NETs on patients' lives and identified key areas for improvement in diagnosis and long-term management, including better access to NET-specific treatments and specialist medical teams/centers.
- Published
- 2017
- Full Text
- View/download PDF
40. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs.
- Author
-
Singh S, Granberg D, Wolin E, Warner R, Sissons M, Kolarova T, Goldstein G, Pavel M, Öberg K, and Leyden J
- Abstract
Purpose: Despite the considerable impact of neuroendocrine tumors (NETs) on patients' daily lives, the journey of the patient with a NET has rarely been documented, with published data to date being limited to small qualitative studies. NETs are heterogeneous malignancies with nonspecific symptomology, leading to extensive health care use and diagnostic delays that affect survival. A large, international patient survey was conducted to increase understanding of the experience of the patient with a NET and identify unmet needs, with the aim of improving disease awareness and care worldwide., Methods: An anonymous, self-reported survey was conducted (online or on paper) from February to May 2014, recruiting patients with NETs from > 12 countries as a collaboration between the International Neuroendocrine Cancer Alliance and Novartis Pharmaceuticals. Survey questions captured information on sociodemographics, clinical characteristics, NET diagnostic experience, disease impact/management, interaction with medical teams, NET knowledge/awareness, and sources of information. This article reports the most relevant findings on patient experience with NETs and the impact of NETs on health care system resources., Results: A total of 1,928 patients with NETs participated. A NET diagnosis had a substantially negative impact on patients' personal and work lives. Patients reported delayed diagnosis and extensive NET-related health care resource use. Patients desired improvement in many aspects of NET care, including availability of a wider range of NET-specific treatment options, better access to NET experts or specialist centers, and a more knowledgeable, better-coordinated/-aligned NET medical team., Conclusion: This global patient-reported survey demonstrates the considerable burden of NETs with regard to symptoms, work and daily life, and health care resource use, and highlights considerable unmet needs. Further intervention is required to improve the patient experience among those with NETs., Competing Interests: Authors’ disclosures of potential conflicts of interest and contributions are found at the end of this article.The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc. Simron SinghHonoraria: Novartis, Pfizer, Ipsen Travel, Accommodations, Expenses: Novartis, Pfizer, IpsenDan GranbergNo relationship to discloseEdward WolinHonoraria: Novartis, Ipsen, Celgene, Advanced Accelerator Applications Consulting or Advisory Role: Novartis, Ipsen, Celgene, Advanced Accelerator ApplicationsRichard WarnerHonoraria: Novartis, Pfizer, Lexicon Pharmaceuticals Consulting or Advisory Role: Novartis, Pfizer, Lexicon Pharmaceuticals Research Funding: Lexicon PharmaceuticalsMaia SissonsResearch Funding: Novartis, Ipsen, PfizerTeodora KolarovaNo relationship to discloseGrace GoldsteinCOO of The Carcinoid Cancer Foundation, Inc.; reports that the Foundation has received grants from Novartis, Ipsen, Advanced Accelerator Applications, and Lexicon Pharmaceuticals Travel, Accommodations, Expenses: NovartisMarianne PavelHonoraria: Ipsen, Lexicon Pharmaceuticals, Novartis, Pfizer Consulting or Advisory Role: Ipsen, Lexicon Pharmaceuticals, Novartis, Pfizer Research Funding: Novartis Travel, Accommodations, Expenses: Ipsen, NovartisKjell ÖbergNo relationship to discloseJohn LeydenPresident of the Unicorn Foundation; reports that the Foundation has received support from Novartis Australia, Pfizer Australia, and Ipsen
- Published
- 2016
- Full Text
- View/download PDF
41. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
- Author
-
Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O'Brien NA, Kolarova T, Finn RS, Linnartz R, Chen D, and Slamon DJ
- Subjects
- Animals, Antibodies, Monoclonal, Humanized administration & dosage, Apoptosis drug effects, Breast Neoplasms genetics, Breast Neoplasms pathology, Cell Line, Tumor, Cell Proliferation drug effects, Estradiol administration & dosage, Estradiol analogs & derivatives, Everolimus, Female, Fulvestrant, Gene Expression Regulation, Neoplastic drug effects, Humans, Mice, Receptor, ErbB-2 genetics, Sirolimus administration & dosage, TOR Serine-Threonine Kinases antagonists & inhibitors, Tamoxifen administration & dosage, Trastuzumab, Xenograft Model Antitumor Assays, Breast Neoplasms drug therapy, Drug Resistance, Neoplasm genetics, Molecular Targeted Therapy, Receptors, Estrogen genetics, Sirolimus analogs & derivatives
- Abstract
Everolimus (RAD001, Afinitor(®)) is an oral, selective mTOR inhibitor recently approved by the US-FDA in combination with exemestane for treatment of hormone receptor positive advanced breast cancer. To date, no molecular predictors of response to everolimus in breast cancer have been identified. We hypothesized predictive markers could be identified using preclinical models. Using a molecularly characterized panel of human breast cancer and immortalized breast epithelial cell lines, we determined sensitivity to everolimus alone or in combination with ER- or HER2- targeted therapy. Gene expression microarrays and comparative genomic hybridization were performed on the cell lines to identify predictors of response to everolimus. Among 13 everolimus-sensitive cell lines, 10/13(77 %) were luminal, while in 26 resistant cell lines, 16/26(62 %) were non-luminal, and 10/26(38 %) were luminal. Only 3/24 non-luminal lines were sensitive, two of which were HER2+. Everolimus enhanced the anti-proliferative effect of both tamoxifen (TAM) and fulvestrant (FUL) in ER+ breast cancer cell lines, as well as trastuzumab in HER2+ cell lines. Everolimus + FUL but not everolimus + TAM reversed acquired resistance to TAM. Everolimus inhibited mTOR in tested cell lines by decreasing S6 phosphorylation, mediating its anti-proliferative effect by G0/G1 cell cycle arrest and induction of apoptosis. Chromosomal amplifications of AURKA (p value = 0.04) and HER2 (p value = 0.03) were each associated with increased sensitivity to everolimus. Transcript expression microarrays identified GSK3A, PIK3R3, KLF8, and MAPK10 among the genes overexpressed in sensitive luminal lines, while PGP, RPL38, GPT, and GFAP were among the genes overexpressed in resistant luminal cell lines. These preclinical in vitro data provide further support for continued clinical development of everolimus in luminal (ER+ or HER2+) breast cancer in combination with targeted therapies. We identified several potential molecular markers associated with response to everolimus that will require validation in clinical material.
- Published
- 2015
- Full Text
- View/download PDF
42. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.
- Author
-
Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, and Finn RS
- Subjects
- Apoptosis, Aurora Kinase A genetics, Aurora Kinase A metabolism, Aurora Kinase B antagonists & inhibitors, Aurora Kinase B genetics, Aurora Kinase B metabolism, Aurora Kinase C antagonists & inhibitors, Aurora Kinase C genetics, Aurora Kinase C metabolism, Breast Neoplasms, Cell Cycle drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Cyclin-Dependent Kinase Inhibitor p21 metabolism, DNA Copy Number Variations, DNA Mutational Analysis, Drug Screening Assays, Antitumor, Female, Gene Expression, Humans, Mutation, Tumor Suppressor Protein p53 metabolism, Antineoplastic Agents pharmacology, Aurora Kinase A antagonists & inhibitors, Phthalazines pharmacology, Tumor Suppressor Protein p53 genetics
- Abstract
Aurora kinases play important roles in cell division and are frequently overexpressed in human cancer. AMG 900 is a novel pan-Aurora kinase inhibitor currently being tested in Phase I clinical trials. We aimed to evaluate the in vitro activity of AMG 900 in a panel of 44 human breast cancer and immortalized cell lines and identify predictors of response. AMG 900 inhibited proliferation at low nanomolar concentrations in all cell lines tested. Response was further classified based on the induction of lethality. 25 cell lines were classified as highly sensitive (lethality at 10 nM of AMG 900 >10 %), 19 cell lines as less sensitive to AMG 900 (lethality at 10 nM of AMG 900 <10 %). Traditional molecular subtypes of breast cancer did not predict for this differential response. There was a weak association between AURKA amplification and response to AMG 900 (response ratio = 2.53, p = 0.09). mRNA expression levels of AURKA, AURKB, and AURKC and baseline protein levels of Aurora kinases A and B did not significantly associate with response. Cell lines with TP53 loss of function mutations (RR = 1.86, p = 0.004) and low baseline p21 protein levels (RR = 2.28, p = 0.0004) were far more likely to be classified as highly sensitive to AMG 900. AMG 900 induced p53 and p21 protein expression in cell lines with wt TP53. AMG 900 caused the accumulation of cells with >4 N DNA content in a majority of cell lines independently of sensitivity and p53 status. AMG 900 induced more pronounced apoptosis in highly sensitive p53-dysfunctional cell lines. We have found that AMG 900 is highly active in breast cancer cell lines and that TP53 loss of function mutations as well as low baseline expression of p21 protein predict strongly for increased sensitivity to this compound in vitro.
- Published
- 2013
- Full Text
- View/download PDF
43. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
- Author
-
Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, and Konecny GE
- Subjects
- Apoptosis drug effects, BRCA2 Protein genetics, Cell Line, Tumor, DNA Fragmentation drug effects, Drug Synergism, Female, Histones genetics, Humans, Mutation, Ovarian Neoplasms genetics, Ovarian Neoplasms pathology, Poly(ADP-ribose) Polymerase Inhibitors, Topotecan administration & dosage, Ubiquitin-Protein Ligases genetics, Histones metabolism, Indoles administration & dosage, Ovarian Neoplasms drug therapy, Poly(ADP-ribose) Polymerases metabolism
- Abstract
Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer. We studied the growth inhibitory effects of rucaparib in a panel of 39 ovarian cancer cell lines that were each characterized for mutation and methylation status of BRCA1/2, baseline gene expression signatures, copy number variations of selected genes, PTEN status, and sensitivity to platinum-based chemotherapy. To study interactions with chemotherapy, we used multiple drug effect analyses and assessed apoptosis, DNA fragmentation, and γH2AX formation. Concentration-dependent antiproliferative effects of rucaparib were seen in 26 of 39 (67%) cell lines and were not restricted to cell lines with BRCA1/2 mutations. Low expression of other genes involved in homologous repair (e.g., BCCIP, BRCC3, ATM, RAD51L1), amplification of AURKA or EMSY, and response to platinum-based chemotherapy was associated with sensitivity to rucaparib. Drug interactions with rucaparib were synergistic for topotecan, synergistic, or additive for carboplatin, doxorubicin or paclitaxel, and additive for gemcitabine. Synergy was most pronounced when rucaparib was combined with topotecan, which resulted in enhanced apoptosis, DNA fragmentation, and γH2AX formation. Importantly, rucaparib potentiated chemotherapy independent of its activity as a single agent. PARP inhibition may be a useful therapeutic strategy for a wider range of ovarian cancers bearing deficiencies in the homologous recombination pathway other than just BRCA1/2 mutations. These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer., (©2013 AACR)
- Published
- 2013
- Full Text
- View/download PDF
44. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
- Author
-
Konecny GE, Kolarova T, O'Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Porta DG, Anderson L, Shi MM, Yovine A, and Slamon DJ
- Subjects
- Animals, Antineoplastic Agents administration & dosage, Antineoplastic Agents chemistry, Benzimidazoles administration & dosage, Benzimidazoles chemistry, Cell Cycle Checkpoints drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Cell Survival genetics, Endometrial Neoplasms genetics, Endometrial Neoplasms pathology, Female, Humans, Inhibitory Concentration 50, Mice, Mutation, Phenylurea Compounds administration & dosage, Phenylurea Compounds chemistry, Pyrimidines administration & dosage, Pyrimidines chemistry, Quinolones administration & dosage, Quinolones chemistry, Receptor, Fibroblast Growth Factor, Type 2 genetics, Signal Transduction drug effects, Tumor Burden drug effects, Tumor Burden genetics, Xenograft Model Antitumor Assays, Antineoplastic Agents pharmacology, Benzimidazoles pharmacology, Endometrial Neoplasms metabolism, Phenylurea Compounds pharmacology, Pyrimidines pharmacology, Quinolones pharmacology, Receptor, Fibroblast Growth Factor, Type 2 antagonists & inhibitors
- Abstract
The recent identification of activating fibroblast growth factor receptor 2 (FGFR2) mutations in endometrial cancer has generated an opportunity for a novel target-based therapy. Here, we explore the therapeutic potential of 2 FGFR inhibitors, the multikinase inhibitor dovitinib (TKI258) and the more selective FGFR inhibitor NVP-BGJ398 for the treatment of endometrial cancer. We examined the effects of both inhibitors on tumor cell growth, FGFR2 signaling, cell cycle, and apoptosis using a panel of 20 molecularly characterized human endometrial cancer cell lines. Anchorage-independent growth was studied using soft agar assays. In vivo studies were conducted using endometrial cancer xenograft models. Cell lines with activating FGFR2 mutations (S252W, N550K) were more sensitive to dovitinib or NVP-BGJ398 when compared with their FGFR2 wild-type counterparts (P = 0.073 and P = 0.021, respectively). Both agents inhibited FGFR2 signaling, induced cell-cycle arrest, and significantly increased apoptosis in FGFR2-mutant lines. In vitro, dovitinib and NVP-BGJ398 were both potent at inhibiting cell growth of FGFR2-mutant endometrial cancer cells, but the activity of dovitinib was less restricted to FGFR2-mutant lines when compared with NVP-BGJ398. In vivo, dovitinib and NVP-BGJ398 significantly inhibited the growth of FGFR2-mutated endometrial cancer xenograft models. In addition, dovitinib showed significant antitumor activity in FGFR2 wild-type endometrial cancer xenograft models including complete tumor regressions in a long-term in vivo study. Dovitinib and NVP-BGJ398 warrant further clinical evaluation in patients with FGFR2-mutated endometrial cancer. Dovitinib may have antitumor activity in endometrial cancer beyond FGFR2-mutated cases and may permit greater flexibility in patient selection., (©2013 AACR)
- Published
- 2013
- Full Text
- View/download PDF
45. Rapidly quantifying drug sensitivity of dispersed and clumped breast cancer cells by mass profiling.
- Author
-
Chun J, Zangle TA, Kolarova T, Finn RS, Teitell MA, and Reed J
- Subjects
- Cell Line, Tumor, Drug Resistance, Neoplasm, Female, Humans, Receptor, ErbB-2 biosynthesis, Trastuzumab, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Interferometry methods
- Abstract
Live cell mass profiling is a promising new approach for rapidly quantifying responses to therapeutic agents through picogram-scale changes in cell mass over time. A significant barrier in mass profiling is the inability of existing methods to handle pleomorphic cellular clusters and clumps, which are more commonly present in patient-derived samples or tissue cultures than are isolated single cells. Here we demonstrate automated Live Cell Interferometry (LCI) as a rapid and accurate quantifier of the sensitivity of single cell and colony-forming human breast cancer cell lines to the HER2-directed monoclonal antibody, trastuzumab (Herceptin). The relative sensitivities of small samples (<500 cells) of four breast cancer cell lines were determined tens-to-hundreds of times faster than is possible with traditional proliferation assays. These LCI advances in clustered sample assessment and speed open up the possibility for therapeutic response testing of patient-derived solid tumor samples, which are viable only for short periods ex vivo and likely to be in the form of cell aggregates and clusters.
- Published
- 2012
- Full Text
- View/download PDF
46. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
- Author
-
Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L, Kalli KR, Finn RS, Ginther C, Jones S, Velculescu VE, Riehle D, Cliby WA, Randolph S, Koehler M, Hartmann LC, and Slamon DJ
- Subjects
- Cell Cycle drug effects, Cell Line, Tumor, Cell Proliferation, Cohort Studies, Dose-Response Relationship, Drug, Female, Genes, p53, Humans, Immunohistochemistry methods, Oligonucleotide Array Sequence Analysis, Phosphorylation, Piperazines pharmacology, Pyridines pharmacology, Cyclin-Dependent Kinase 4 metabolism, Cyclin-Dependent Kinase 6 metabolism, Cyclin-Dependent Kinase Inhibitor p16 metabolism, Gene Expression Regulation, Neoplastic, Genes, p16, Ovarian Neoplasms metabolism, Retinoblastoma Protein metabolism
- Abstract
Purpose: PD-0332991 is a selective inhibitor of the CDK4/6 kinases with the ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. Here we investigate the role of CDK4/6 inhibition in human ovarian cancer., Experimental Design: We examined the effects of PD-0332991 on proliferation, cell-cycle, apoptosis, and Rb phosphorylation using a panel of 40 established human ovarian cancer cell lines. Molecular markers for response prediction, including p16 and Rb, were studied using gene expression profiling, Western blot, and array CGH. Multiple drug effect analysis was used to study interactions with chemotherapeutic drugs. Expression of p16 and Rb was studied using immunohistochemistry in a large clinical cohort of ovarian cancer patients., Results: Concentration-dependent antiproliferative effects of PD-0332991 were seen in all ovarian cancer cell lines, but varied significantly between individual lines. Rb-proficient cell lines with low p16 expression were most responsive to CDK4/6 inhibition. Copy number variations of CDKN2A, RB, CCNE1, and CCND1 were associated with response to PD-0332991. CDK4/6 inhibition induced G0/G1 cell cycle arrest, blocked Rb phosphorylation in a concentration-and time-dependent manner, and enhanced the effects of chemotherapy. Rb-proficiency with low p16 expression was seen in 97/262 (37%) of ovarian cancer patients and was independently associated with poor progression-free survival (adjusted relative risk 1.49, 95% CI 1.00-2.24, P = 0.052)., Conclusions: PD-0332991 shows promising biologic activity in ovarian cancer cell lines. Assessment of Rb and p16 expression may help select patients most likely to benefit from CDK4/6 inhibition in ovarian cancer., (©2011 AACR.)
- Published
- 2011
- Full Text
- View/download PDF
47. [Study of the absorption, distribution and elimination of some intravenous anesthetics by labelling them with 113m In].
- Author
-
Atanasov A, Kolarova T, and Popova M
- Subjects
- Absorption, Animals, Barbiturates metabolism, Indium, Rabbits, Radioisotopes, Time Factors, Anesthesia, Intravenous, Anesthetics metabolism
- Published
- 1975
48. [Comparative studies on the basal metabolism and radioactive 131-I accumulation test in the thyroid gland in patients with thyrotoxicosis].
- Author
-
Tzonev K, Kolarova T, and Iliev E
- Subjects
- Adult, Humans, Iodine Radioisotopes, Middle Aged, Basal Metabolism, Hyperthyroidism diagnosis, Thyroid Function Tests, Thyroid Gland metabolism
- Published
- 1968
49. [Color-scintigraphy of the heart cavities and great vessels].
- Author
-
Bozduganov A, Ignatov A, and Kolarova T
- Subjects
- Heart Defects, Congenital diagnosis, Humans, Indium, Methods, Radioisotopes, Cardiovascular Diseases diagnosis, Color, Radionuclide Imaging
- Published
- 1973
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.